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Abstract
Peptidyl-prolyl cis/trans isomerases (PPIs) catalyze cis/trans isomerization of peptide bonds preceding proline residues. The
involvement of PPI family members in protein refolding has been established in test tube experiments. Surprisingly,
however, no data is available on the involvement of endoplasmic reticulum (ER)-resident members of the PPI family in
protein folding, quality control or disposal in the living cell. Here we report that the immunosuppressive drug cyclosporine
A (CsA) selectively inhibits the degradation of a subset of misfolded proteins generated in the ER. We identify cyclophilin B
(CyPB) as the ER-resident target of CsA that catalytically enhances disposal from the ER of ERAD-LS substrates containing cis
proline residues. Our manuscript presents the first evidence for enzymatic involvement of a PPI in protein quality control in
the ER of living cells.
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Introduction
Formation and reduction of covalent bonds between cysteine
side chains and cis/trans isomerization of peptide bonds preceding
proline residues are rate-determining steps for the attainment of
the native and functional 3D structure of polypeptides synthesized
in the ER. These reactions might also be rate-limiting for the
unfolding of aberrant polypeptides that require retro-translocation
(dislocation) across the ER membrane for proteasomal degrada-
tion [1]. In vitro, these reactions are catalyzed by protein disulfide
isomerases (PDIs [2]) and by PPIs [3,4], respectively. Extensive
experimental evidence has shown the importance of PDIs-assisted
polypeptide folding and unfolding in living cells [5,6]. Despite 25
years of PPI catalysis experiments in vitro, a direct involvement of
PPIs in catalysis of protein folding, in regulation of protein quality
control or in clearance of misfolded polypeptides from the ER of
living cells remains to be demonstrated [7,8,9].
Most polypeptides entering the ER lumen are covalently
modified at asparagine side chains with glucose3-mannose9-N-
acetylglucosamine2- oligosaccharides. Their maturation is assisted
by a dedicated folding machinery comprising the oligosaccharide-
binding chaperones calnexin and calreticulin and the oxidoreduc-
tase ERp57 [10]. Processing of oligosaccharides displayed on
misfolded conformers by ER-resident a1,2-mannosidases, with
removal of up to 4 terminal mannose residues, irreversibly extracts
folding-defective polypeptides from the lectin-operated folding
machinery [11]. In mammalian cells, two ER-associated degradation
(ERAD) shuttles, OS-9 and XTP3-B [12,13,14], transport ERAD-LS
substrates (i.e. Soluble, extensively de-mannosylated terminally
misfolded glycopolypeptides) from the ER lumen to the site of
dislocation across the ER membrane [15]. OS-9 and XTP3-B
deliver ERAD-LS substrates to a multi-protein complex comprising
the membrane receptor SEL1L, the associated E3 ubiquitin ligase
HRD1 and an elusive dislocation (retro-translocation) channel [16].
The stringent requirement for HRD1, SEL1L and OS-9/XTP3-B
for disposal is bypassed when the same misfolded domains are
tethered to the ER Membrane (ERAD-LM substrates) [15,17]. Thus,
luminal misfolded polypeptides and membrane-tethered polypep-
tides with structural defects in the ER lumen have different
requirements for efficient clearance from the ER.
Although the process of dislocation across the ER membrane is
poorly defined, unfolding of aberrant polypeptide chains [18] and
disassembly of disulfide-bonded protein aggregates [19] have been
shown to facilitate protein clearance from the ER lumen. A role in
ERAD has been demonstrated for several members of the PDI
superfamily (e.g. PDI, ERp57, ERp72, ERp29, ERdj5), thus
implying that reduction of inter- and intra-molecular disulfide
bonds plays a crucial role in ERAD by eliminating tertiary and
quaternary structures that could impair transport across a putative
proteinaceous membrane dislocon (reviewed in [5]). On the same
line, it is conceivable that the PPIs-catalyzed interconversion of cis
into trans peptidyl-prolyl bonds could facilitate dislocation of
ERAD substrates across the ER membrane by eliminating turns in
the polypeptide secondary structure [9].
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specific inhibitor of the cyclophilin family of PPIs, selectively
delays the degradation of the ERAD-LS substrate BACE457D
leaving unaffected disposal from the ER of the same polypeptide
when tethered to the ER membrane (the ERAD-LM protein
BACE457). This identifies CsA as the first inhibitor that selectively
acts upon an ERAD-LS substrate and not upon the corresponding
ERAD-LM polypeptide. We then extend this finding by showing
that, among roughly 20 mammalian cyclophilin family members,
CyPB is unique because it plays a crucial role in ERAD that
requires its enzymatic activity. Importantly, CsA is not a general
inhibitor of the ERAD-LS pathway and CyPB is not required for
disposal of all ERAD-LS substrates. Rather, the presence of
peptidyl-prolyl bonds in the cis conformation renders disposal of
ERAD-LS substrates sensitive to CsA and dependent on CyPB
intervention. Altogether, our manuscript presents the first evidence
for the enzymatic involvement of a PPI in protein quality control
in the ER of a living cell.
Results and Discussion
CsA selectively inhibits disposal of BACE457D
BACE457 and BACE457D are splice variants of the human
beta-site amyloid precursor protein cleaving enzyme BACE501
[20], an aspartic protease involved in generation of the Ab peptide
that forms plaques in the brain of Alzheimer’s disease patients. A
44-residue deletion in the ectodomain prevents attainment of the
native structure and results in degradation from the ER lumen
when the proteins are ectopically expressed in cultured cells.
Proteasome-dependent disposal of both proteins requires inter-
vention of EDEM variants and extensive de-mannosylation of the
2 protein-bound N-glycans [19,21,22,23]. However, degradation
of BACE457D, an ERAD-LS protein, strictly depends on HRD1,
SEL1L and OS-9/XTP3-B, while disposal of BACE457, an
ERAD-LM protein, progresses efficiently even upon inactivation of
the HRD1 pathway [15].
BACE457 and BACE457D contain 26 and 25 proline residues,
respectively. It is impossible to establish if, and which one of the
peptidyl bonds preceding these proline residues is converted from
the trans to the cis configuration during the short retention of
these folding-defective polypeptides in the ER lumen. It is of
interest, however, that in the folding competent variant BACE501
the peptidyl bonds preceding Pro84, Pro146 and Pro390 are in
the cis configuration (see below and Materials and Methods). To
assess whether prolyl isomerases might facilitate disposal of
BACE457 and BACE457D from the mammalian ER, we exposed
cells transiently transfected for expression of either one of the two
model substrates to CsA, a selective inhibitor of immunophilin
members of the PPIs family [24]. CsA-treatment was compared
with cell exposure to a series of well-characterized ERAD
inhibitors (thapsigargin (Tg, which inhibits the SERCA pump
thus depleting luminal calcium [25]); kifunensine (Kif, an
inhibitor of a1,2-mannosidases [26]); PS341 (a proteasome
inhibitor [27])).
Seventeen hours after cell transfection, the ectopically expressed
ERAD substrates were metabolically labeled for 10 min by
incubating cells in a media containing
35S-methionine and -
cysteine. The initial amount of labeled BACE457 (Figs. 1A–1B)
or BACE457D (Figs. 1C–1D) was immunoisolated from cell
lysates prepared after 10 min of chase in the absence of
radioactivity (lane 1). To monitor ERAD, the residual amount of
labeled BACE457 or BACE457D was immunoisolated after 120 or
75 min of chase, respectively, from mock-treated cells (lane 2) or
from cells exposed to CsA, Tg, Kif or PS341 (lanes 3–6).
Confirming published data [19,21,22,23], Tg, Kif and PS341
substantially delayed disposal of both BACE457 and BACE457D
(Figs. 1A–1D). CsA did not inhibit degradation of BACE457
(Figs. 1A–1B, lane 3 vs lane 2 and Figs 2B–2C, lanes 1–3), but
substantially delayed the clearance from the ER lumen of
BACE457D (Figs. 1C–1D, lane 3 vs lane 2 and Figs 2D–2E,
3B–3C, lanes 1–3) as efficiently as the conventional ERAD
inhibitors Tg, Kif and PS341 (Figs. 1C–1D, lanes 4–6). To
summarize, we identify CsA as the first compound that selectively
inhibits disposal of a soluble (ERAD-LS), but not of a membrane-
tethered (ERAD-LM) variant of a misfolded polypeptide.
CsA is not a general inhibitor of the ERAD-LS pathway
To determine whether CsA is a general inhibitor of the ERAD-
LS pathway, we next checked whether cell exposure to CsA
delayed disposal of CD3dD. Like BACE457D, this tri-glycosylated,
soluble and folding-defective ERAD-LS protein stringently de-
pends on HRD1, SEL1L and OS-9/XTP3-B for efficient disposal
[15]. As expected for an ERAD substrate, disposal of CD3dD was
substantially delayed upon inactivation of protein de-mannosyla-
tion and upon inactivation of 26S proteasomes (Figs. 1E–1F,
lanes 4 and 5, respectively). However, CsA was ineffective in
preventing clearance of CD3dD from the ER (lane 3). Thus, even
though CsA substantially delayed disposal of the ERAD-LS
protein BACE457D (and of other canonical ERAD-LS substrates
such as BACE476D (Figs. 1G–1H) and NHK, a folding-defective
version of the secretory protein a1-antitrypsin (Figs. 1I–1L)), the
incapacity of CsA to prevent CD3dD disposal showed that CsA is
NOT a general inhibitor of the ERAD-LS pathway.
Why is the disposal of CD3dD insensitive to CsA and the
disposal of other ERAD-LS substrates efficiently delayed by this
PPI inhibitor? It is possible that none of the peptidyl-prolyl bonds
of the misfolded CD3dD retained in the ER lumen is in the cis
configuration, while one or more peptidyl-prolyl bonds of the
misfolded BACE variants are in cis and must be isomerized to the
trans conformation to promote efficient clearance from the ER. Of
some relevance in this context could be that the corresponding
native proteins do not have (the CD3d in the functional T cell
receptor) or do have peptidyl-prolyl bonds in the cis conformation
(the native BACE501, Materials and Methods). We therefore
hypothesized that the presence of peptidyl-prolyl bonds in the cis
conformation determines CsA-sensitivity for the disposal of
ERAD-LS polypeptides from the mammalian ER (see next
sections).
CyPB is the luminal CsA target involved in ERAD
CsA is a cyclic undecapeptide produced by the fungus
Tolypocladium inflatum gams. It is used in the clinic as an
immunosuppressant to reduce the risk of graft rejection upon
allogenic transplant and to improve short-term allograft survival
[28]. The PPI family member CyPB is the ER-resident target of
CsA [29]. A role for CyPB (or of any other PPI family member) in
catalysis of peptidyl-prolyl cis/trans isomerization in protein
biogenesis and/or quality control in the ER of living cells is not
supported by experimental data. To determine whether CyPB
intervenes in protein disposal from the ER lumen, we compared
degradation of the ERAD-LM, CsA-insensitive substrate
BACE457 (Figs. 2B–2C) and of the ERAD-LS, CsA-sensitive
substrate BACE457D (Figs. 2D–2E) in cells with normal level of
CyPB (lanes 1–3), with reduced level of CyPB (lanes 4–6) or with
reduced level of CyPA, a cytosolic target of CsA (lanes 7–9).
Down-regulation of the target proteins upon specific RNA
interference is shown in Fig. 2A. The data shown in Figs. 2B–
2C confirmed that cell exposure to CsA does not significantly
CyPB and ERAD
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e13008delay disposal of the membrane-tethered BACE457 from the ER
lumen (compare lane 2 with 3). Down-regulation of CyPB
(Figs. 2B–2C, lanes 4–6) or of CyPA (lanes 7–9) had no
significant consequences on BACE457 disposal. Thus, CyPB is
dispensable for disposal of this ERAD-LM substrate.
As shown in Figs. 1C–1D, CsA substantially inhibited disposal
of BACE457D (Figs. 2D–2E, lane 3 vs lane 2). Consistent with
the identification of CyPB as the intracellular target of CsA
modulating disposal of this ERAD-LS substrate, the down-
regulation of CyPB substantially delayed BACE457D disposal
(Figs. 2D–2E, lane 5 vs lane 2). Exposure of cells with low
intralumenal content of CyPB to CsA had a minor, additional
inhibitory effect on BACE457D disposal (lane 6 vs lane 5) possibly
due to the inhibition of the residual CyPB remaining in the cells
subjected to specific RNAi (Fig. 2A, lane 2). In contrast, the
down-regulation of CyPA did not delay BACE457D disposal (lane
8 vs lane 2) and CsA maintained the inhibitory effect on
BACE457D disposal in cells with low levels of CyPA (lane 9).
The disposal of CD3dD that was insensitive to CsA (Figs. 1E–1F)
was also not inhibited upon variations in the intracellular levels of
CyPB and of CyPA (Figs. 2F–2G).
These data are consistent with a selective involvement of the
luminal immunophilin CyPB in clearance of ERAD-LS substrates
characterized by the presence of cis proline residues.
The enzymatic activity of CyPB is required to regulate
ERAD
The data shown so far are consistent with a model in which
CyPB facilitates BACE457D disposal by assisting the enzymatic
Figure 1. Consequences of CsA-treatment on disposal of ERAD-LM and ERAD-LS substrates. A Labeled BACE457, an ERAD-LM substrate,
was immunoisolated from total cell extracts with a specific antibody after 10 (lane 1, initial amount) or 120 min of chase (lane 2, residual amount).
Labeled BACE457 was also immunoisolated from cells exposed for 120 min to CsA (lane 3), Tg (lane 4), Kif (lane 5) or PS341 (lane 6). B Quantification
of the labeled polypeptide bands shown in the gel. Reproducibility of these data (i.e. lack of CsA inhibition) is confirmed by the independent
experiment shown in Figs. 2B–2C, lanes 1–3. C Same as A for BACE457D, an ERAD-LS substrate. Chase times are 10 (initial) and 75 min (residual). The
apparent mass of BACE457D is reduced by the progressive and extensive de-mannosylation of the protein-bound oligosaccharides during the chase
(lane 1 vs 2 [19,35,36]). Consistently, enhancement in electrophoretic mobility is specifically inhibited by Kif (lane 5 in Figs. 1A and 1C; lane 4 in Figs.
1E and 1G [26]). CsA, Tg and PS341 inhibit BACE457D disposal without affecting the enhancement of electrophoretic mobility during the chase.
Thus, they all affect events occurring after substrate de-mannosylation. D Same as B for BACE457D. The reproducibility is confirmed in Figs. 2D–2E,
lanes 1–3. E Same as A for CD3dD, an ERAD-LS substrate lacking cis peptidyl-prolyl bonds. F Same as B for CD3dD. The reproducibility is confirmed in
Figs. 2F–2G, lanes 1–3. G Same as A for BACE476D. H Same as B for BACE476D. I Same as A for NHK. L Same as B for NHK.
doi:10.1371/journal.pone.0013008.g001
CyPB and ERAD
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the cis into the trans configuration. This could eliminate turns in the
polypeptide chain thus facilitating protein dislocation across the
ER membrane, which is required for ERAD and occurs through
an elusive proteinaceous channel [16]. Alternatively, peptidyl-
prolyl isomerization could facilitate another rate-determining step
in the disposal pathway of ERAD-LS substrates, for example their
dissociation from a luminal retention factor. To assess whether the
catalytic activity of CyPB is required for BACE457D disposal, an
active and a catalytically inactive CyPB carrying a R62A mutation
Figure 2. Consequences of CyPB or CyPA down regulation on BACE457, BACE457D and CD3dD disposal from the ER. A Down-
regulations of CyPB and of CyPA were assessed by immunoblot of total cell lysates. Tubulin is a loading control. B Radiolabeled BACE457 was
immunoisolated at the end of the chase times from detergent-extracts of cells expressing a scrambled siRNA (siSCR, lanes 1–3), a siRNA targeting
CyPB (siCyPB, lanes 4–6) or CyPA (siCyPA, lanes 7–9) and exposed to CsA (lanes 3, 6 and 9). C Quantification of the labeled polypeptide bands. D
Same as B for BACE457D. E same as C for BACE457D. Error bars represent SD from the mean of at least three independent experiments. F Same as B
for CD3dD. G Same as C for CD3dD.
doi:10.1371/journal.pone.0013008.g002
CyPB and ERAD
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[30] were back transfected in cells with a reduced content of
endogenous CyPB (Fig. 3A). Both recombinant CyPB and
CyPBR62A carried three silent mutations in their coding sequence
to render their transcripts resistant to the small interfering RNA
used to down-regulate endogenous CyPB. Ectopic expression of
CyPB in cells with reduced level of the endogenous protein re-
established efficient disposal of BACE457D (Figs. 3B–3C, lane 8
vs lane 5). In these cells, like in cells with normal content of
endogenous CyPB (lanes 1–3), exposure to CsA substantially
delayed BACE457D disposal (lane 9 vs lane 8). In contrast, ectopic
expression of the enzymatically inactive CyPBR62A was not
sufficient to recover BACE457D disposal in cells depleted of the
endogenous enzyme (lane 11 vs lanes 2 and 8). This indicates that
the enzymatic activity is required for CyPB-assisted acceleration of
BACE457D disposal and implies that enzymatic conversion of one
or more of the cis peptidyl-prolyl bonds of BACE457D facilitates
disposal of the terminally misfolded polypeptide. These results are
also consistent with the finding that CyPB is dispensable for
efficient disposal of CD3dD, an ERAD-LS substrate lacking
proline residues in the cis configuration (Figs. 1E–1F and
Figs. 2F–2G).
Cis proline replacement abrogates CsA-sensitivity and
CyPB-dependency of ERAD
BACE457D has 24 proline residues. It is impossible to establish
which peptidyl-prolyl bond needs to be interconverted from the cis
into the trans configuration during the short retention in the ER
lumen that precedes dislocation into the cytosol of this folding-
defective polypeptide. However, we determined whether replace-
ment of Pro84, 146 and 390 (which are in cis in the stable
BACE501 splice variant) with alanine residues relieved the CyPB-
dependency for efficient disposal.
Consistent with a CsA-insensitive ERAD pathway for ERAD-
LS proteins lacking cis proline residues (Figs. 1E–1F), disposal of
BACE457DP84,146,390A was not inhibited by cell incubation with
CsA (Figs. 4A–4B). Similarly, while reduction in the intralumenal
level of endogenous CyPB substantially delayed disposal of the wt
BACE457D (Figs. 2–3), degradation of BACE457DP84,146,390A
remained unperturbed upon depletion of the ER-resident
immunophilin (Figs. 4C–4D, lanes 4–6 vs 1–3). Taken together,
these data show that the enzymatic activity of CyPB is only
required for disposal of non-membrane tethered BACE457D
containing cis peptidyl-prolyl bonds.
All in all, CsA was identified as the first selective inhibitor of
disposal of a soluble (ERAD-LS), but not of a membrane-tethered
(ERAD-LM) version of a misfolded polypeptide with luminal
structural defects. Thisconfirms that tethering at the ER membrane
changes the requirements for efficient polypeptide clearance from
the mammalian ER lumen [15]. The CsA-sensitive step of ERAD
occurs after substrate de-mannosylation and before intervention of
cytosolic proteasomes (both progressing unperturbed in cells
exposed to CsA (legend of Fig. 1C and [31]). We identify CyPB
as the ER-resident target of CsA involved in disposal from the
mammalian ER of some (e.g., BACE457D, BACE476D, NHK) but
not all (e.g., CD3dD) ERAD-LS substrates. We provide evidence
that the intervention of CyPB in ERAD requires a functional active
site. As such, our data are the first demonstration of enzymatic
intervention of a member of the PPI superfamily in protein quality
Figure 3. Reversibility of the ERAD defect requires back-transfection of enzymatically active CyPB. A Down-regulation of CyPB and
back-transfections of active or catalytically inactive (R62A) CyPB were assessed by immunoblot of total cell lysates. Tubulin is a loading control. B
Radiolabeled BACE457D was immunoisolated at the end of the chase times from detergent-extracts of cells expressing normal levels of CyPB (siSCR,
lanes 1–3), in cells with reduced level of CyPB (siCyPB, lanes 4–6), in cells with reduced level of CyPB back-transfected with active (siCyPB+CyPB, lanes
7–9) or catalytically inactive CyPB (siCyPB+CyPBR62A, lanes 10–12). C Quantification of the labeled polypeptide bands. Error bars represent SD from at
least two independent experiments.
doi:10.1371/journal.pone.0013008.g003
CyPB and ERAD
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peptidyl-prolyl bonds in the cis configuration is a characteristic of
those ERAD-LS substrates that show CsA-sensitive, CyPB-depen-
dent disposal. For these misfolded polypeptides, consequences of
CsA exposure or of reduction in the intralumenal level of CyPB are
comparable to consequences of inactivation of components of the
dislocon complex built around the membrane-embedded E3
ubiquitin ligase HRD1 that are stringently required for disposal of
ERAD-LS proteins [15]. Our hypothesis that CyPB participates in
the HRD1/ERAD-LS pathway is consistent with a recent report
showing that CyPB forms a functional complex with GRP94,
another component of the HRD1 pathway [14], to protect cells
against ERstress[32].Finally, ourdata implythat unfoldingof non-
native polypeptides upon cis to trans isomerization of peptidyl-prolyl
bonds might facilitate dislocation across the ER membrane [9]
similarly to what has been proposed for polypeptide unfolding upon
PDI-catalyzed reduction of intra- and inter-molecular disulfide
bonds [5]. Alternatively, it could promote dissociation of misfolded
polypeptides from ER retention factors thus facilitating dislocation
across the ER membrane.
Materials and Methods
Expression plasmids, antibodies and inhibitors
Plasmids and antibodies for NHK, CD3dD and BACE variants
are described in [15,23]. The plasmid for CyPB expression is
described in [33]. Primers for silent mutations that protect ectopic
CyPB from siRNA (CyPB, 59-AAAGA CTGTTCCAAAAACCG-
TAGACAATTTTGTGGCCTTAGCT-39). Primers for genera-
tionofinactiveCyPBR62A (59-GGCTACAAAAACAGCAAATTC-
CATGCTGTAAT CAAGGACTTCATG-39). Primers for gen-
eration of BACE457DP84,146,390A, which lacks cis prolines (59-
CCGTGGGCAG GCCCCGCAGACG-39,5 9-GGCACCGAC-
CTGGCTGACGAC TCCC-39,5 9-CAGCGGTGGAAGGCG-
CTTTTGTCACCTTG-39). Mutants were generated using the
site-directed mutagenesis kit (Stratagene). DNA preparations were
obtained usingcommerciallyavailable purificationkits (Sigma). The
nucleotide sequences of all plasmids were verified on both strands.
Antibodies against CyPB, CyPA and Tubulin were from ABR,
Biomol and ABM. The proteasome inhibitor PS341 was a kind gift
of Millenium Pharmaceuticals Inc and was used at a concentration
of 9 mM. Kifunensine (Toronto Research Chemicals Inc), thapsi-
gargin (Sigma) and CsA (Bedford Labs) were used at a
concentration of 100 mM, 300 nM and 20 mM, respectively. All
inhibitors were only included in the chase media.
Cell Lines, transient transfections, RNA interferences,
metabolic labelling, immunoprecipitations, immunoblots
and analysis of data
HeLa cells (from ATCC) were grown in MEM Alpha
supplemented with 10% FBS. Cells at 80–90% confluence in a
Figure 4. Consequences of CsA-treatment and of CyPB down regulation on disposal of BACE457D in which the three cis proline
have been replaced by alanine residues. A Radiolabeled BACE457DP84,146,390A was immunoisolated from total cell extracts after 10 min (lane 1)
or 75 min of chase (lane 2), or from cells exposed for 75 min to CsA (lane 3). B Quantification of the labeled polypeptide bands. C Radiolabeled
BACE457D P84,146,390A was immunoisolated at the end of the chase times from detergent-extracts of cells expressing a scrambled siRNA (siSCR, lanes
1–3) or a siRNA targeting CyPB (siCyPB, lanes 4–6). D Quantification of the labeled polypeptide bands.
doi:10.1371/journal.pone.0013008.g004
CyPB and ERAD
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plasmid of interest (4 mg for single transfections, 6 mg total DNA
for double transfections) using Lipofectamine2000 (Invitrogen)
according to the manufacturer instructions. Experiments were
normally performed 17 hours after transfection. For siRNA-based
interference, HeLa cells at 50% confluence in a 3.5 tissue culture
plate were transfected with siRNA duplex (Ambion Inc, 50 pmol/
dish) using Lipofectamine2000 according to the manufacturer
instructions. Four hours after transfection, the medium was
replaced with MEM Alpha supplemented with 1% of non-
essential amino acids (GIBCO). Thirty hours after siRNA
transfection, cells were transfected with the expression plasmids
of interest. Experiments were performed 48 hours post-siRNA
transfection. siRNA targeting sequences: CyPB: CAAAAACA-
GUGGAUAAUUU; CyPA: CUGGAUUGCAGAGUUAAGU.
Seventeen hours after transfection, cells were starved for 20 min
in Met/Cys free medium, pulsed for 10 min with 50 mCi
[S
35]Met/Cys and chased for the indicated times with MEM
Alpha supplemented with 5 mM cold Met/Cys. Postnuclear
supernatants (PNS) were prepared by solubilization of cells in
400 ml/3,5 cm dish (or 800 ml/6 cm dish) ice-cold 2% CHAPS
(Anatrace) in HEPES-buffered saline (HBS), pH 6.8 containing
20 mM N-ethylmaleimide and protease inhibitors. CHAPS-
insoluble material was separated by centrifugation at 10’000 g
for 10 min. Immunoprecipitations were performed by adding
protein A beads (Sigma; 1:10, w/v swollen in HBS) with the
selected antibody for 2h at 4uC. Immunoprecipitates were
extensively washed (3610 min) with 0.5% CHAPS in HBS,
resuspended in sample buffer, boiled for 5 min and finally
separated in SDS-PAGE. Gels were exposed to BioMax (Kodak)
films and scanned with an Agfa scanner. Relevant bands were
quantified by ImageQuant software (Molecular Dynamics).
Immunoblots were performed using the SNAP i.d. protein
detection system (Millipore). All primary antibodies were used at
1:200–1:333 dilutions. Secondary antibodies were HRP-conjugat-
ed and used at 1:10’000 dilutions. The ECL-Plus detection system
was from Amersham.
Proline residues in the cis conformation
Identification of proline residues in the cis conformation was
done by using the WHAT IF Wb Interface (http://swift.cmbi.ru.
nl/servers/html/index.html) [34].
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